Bioasis Develops MRM-MS Assay for Measurement of Alzheimer's Protein Biomarker
December 17, 2010
Bioasis Develops MRM-MS Assay for Measurement of Alzheimer's Protein Biomarker
The assay, which uses SISCAPA MRM-MS to measure serum levels of melanotransferrin – a protein that a number of studies have tied to Alzheimer's – marks an example of mass spec-based proteomics' ongoing move into the clinical setting.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Automation, Increased Throughput Key to Moving Mass Spec-Based Proteomics into the Clinic
February 11, 2011 / ProteoMonitor - Leigh Anderson Launches New Firm to Commercialize SISCAPA Technology
June 17, 2011 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - New Products
July 29, 2011 / ProteoMonitor - Biocius Buy Key to Agilent's Clinical Proteomics Plans
March 4, 2011 / ProteoMonitor